Corrigendum to ‘‘An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension” [Regul. Toxicol. Pharmacol. 2012, 95–103]
- Resource Type
- Erratum
- Source
- In
Regulatory Toxicology and Pharmacology December 2012 64(3):490-490 - Subject
- Language
- ISSN
- 0273-2300